Get the Stockscreener App
11.78
1.34%
-0.16
Ocular Therapeutix Inc stock is traded at $11.78, with a volume of 3.11M.
It is down -1.34% in the last 24 hours and down -9.73% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$11.94
Open:
$11.93
24h Volume:
3.11M
Relative Volume:
1.20
Market Cap:
$2.05B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-8.7259
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
+3.24%
1M Performance:
-9.73%
6M Performance:
+83.92%
1Y Performance:
+27.77%
1-Day Range:
$11.34
$12.02
1-Week Range:
$10.85
$12.54
52-Week Range:
$5.80
$13.85
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
11.78 | 2.53B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
How risky is Ocular Therapeutix Inc. (0OT) stock compared to peersRecession Risk & Weekly Chart Analysis and Guides - newser.com
Why analysts upgrade Ocular Therapeutix Inc. stock2025 Retail Activity & High Yield Stock Recommendations - newser.com
Using Ichimoku Cloud for Ocular Therapeutix Inc. technicals2025 Bull vs Bear & Smart Allocation Stock Reports - newser.com
Todd Anderman Sells 11,132 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock - MarketBeat
FY2025 EPS Estimate for Ocular Therapeutix Raised by Analyst - MarketBeat
Ocular Therapeutix chief legal officer Anderman sells $137k in stock - Investing.com Canada
How to track smart money flows in Ocular Therapeutix Inc.July 2025 Fed Impact & AI Driven Price Forecasts - newser.com
Using AI based signals to follow Ocular Therapeutix Inc.Earnings Recap Summary & Safe Investment Capital Preservation Plans - newser.com
Can Ocular Therapeutix Inc. stock maintain growth trajectoryTrade Volume Report & Low Risk Profit Maximizing Plans - newser.com
Ocular Therapeutix (NASDAQ:OCUL) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
What machine learning models say about Ocular Therapeutix Inc.IPO Watch & Trade Opportunity Analysis - newser.com
Published on: 2025-10-10 03:24:04 - newser.com
Using R and stats models for Ocular Therapeutix Inc. forecastingMarket Risk Analysis & Smart Allocation Stock Reports - newser.com
Is Ocular Therapeutix Inc. (0OT) stock considered safe haven2025 Market Outlook & Reliable Breakout Forecasts - newser.com
Price action breakdown for Ocular Therapeutix Inc.2025 Retail Activity & Weekly Stock Breakout Alerts - newser.com
WilmerHale Advised Ocular Therapeutix™ in $475 Million Underwritten Offering - WilmerHale
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL): HC Wainwright & Co. Raises Price Targ - GuruFocus
Piper Sandler Lifts PT on Ocular Therapeutix (OCUL) to $31 From $21 - Yahoo Finance
Ocular Therapeutix, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ocular Therapeutix (OCUL) Falls Hard on $475-Million Share Sale - MSN
Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewswire
Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $106,472.59 in Stock - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Insider Jeffrey Heier Sells 10,502 Shares - MarketBeat
What analysts say about Ocular Therapeutix Inc stockGap Up/Gap Down Analysis & Free Rapid Wealth Building - earlytimes.in
Why Ocular Therapeutix Inc. (0OT) stock is trending on social mediaLong Setup & Technical Pattern Alert System - newser.com
Ocular Therapeutix (OCUL) Is Down 8.9% After $475M Equity Raise to Fund Axpaxli Trials — Has the Bull Case Changed? - Sahm
Exit strategy if you’re trapped in Ocular Therapeutix Inc.July 2025 Summary & Long-Term Growth Portfolio Plans - newser.com
Will Ocular Therapeutix Inc. stock deliver long term returns2025 Momentum Check & Technical Pattern Recognition Alerts - newser.com
Published on: 2025-10-05 03:10:01 - newser.com
Looking at the Changing Narrative for Ocular Therapeutix After Recent Analyst Updates - Yahoo Finance
Ocular Therapeutix (NASDAQ:OCUL) Stock Rating Upgraded by Zacks Research - MarketBeat
Ocular Therapeutix (OCUL): Exploring Valuation as Investor Interest Grows in Biotech Prospects - Sahm
Ocular Therapeutix (OCUL) Analyst Rating Update: Piper Sandler Raises Price Target | OCUL Stock News - GuruFocus
Ocular Therapeutix (OCUL) Receives Upgraded Price Target from Ba - GuruFocus
Baird Maintains Ocular Therapeutix (OCUL) Outperform Recommendation - Nasdaq
Published on: 2025-10-02 20:18:07 - newser.com
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Analyst Rating Update: Chardan Capital Maintains Buy | OCUL Stock News - GuruFocus
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
RBC Capital Sticks to Its Buy Rating for Ocular Therapeutix (OCUL) - The Globe and Mail
Needham Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 5.2%Here's Why - MarketBeat
Needham Raises Price Target for OCUL, Maintains Buy Rating | OCU - GuruFocus
Needham & Company LLC Raises Ocular Therapeutix (NASDAQ:OCUL) Price Target to $20.00 - MarketBeat
JMP Securities Maintains Ocular Therapeutix (OCUL) Market Outperform Recommendation - Nasdaq
Ocular Therapeutix's Axpaxli Drug Trials for Wet AMD Poised for Success, RBC Capital Says - MarketScreener
Is Ocular Therapeutix Inc. forming a reversal patternWeekly Trade Analysis & Fast Moving Stock Trade Plans - newser.com
How Ocular Therapeutix Inc. (0OT) stock responds to job market shiftsWeekly Profit Analysis & Fast Entry Momentum Alerts - newser.com
Ocular Therapeutix, Inc. $OCUL Shares Acquired by Deltec Asset Management LLC - MarketBeat
Ocular Therapeutix reports progress in eye disease treatment trials By Investing.com - Investing.com Nigeria
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):